Literature DB >> 20446881

Different apolipoprotein E, apolipoprotein A1 and prostaglandin-H2 D-isomerase levels in cerebrospinal fluid of schizophrenia patients and healthy controls.

Daniel Martins-De-Souza1, Thomas Wobrock, Inga Zerr, Andrea Schmitt, Joanna Gawinecka, Thomas Schneider-Axmann, Peter Falkai, Christoph W Turck.   

Abstract

OBJECTIVES: To identify proteins differentially expressed in schizophrenia patients, we collected 50 microl cerebrospinal fluid from 17 first-episode schizophrenia patients and 10 healthy controls.
METHODS: Their proteins were separated by two-dimensional gel electrophoresis without using any depletion method and identified by mass spectrometry.
RESULTS: Approximately 550 spots were detected, six of which had significantly different intensities in schizophrenia compared to control specimens. We were able to validate in individual samples the upregulation of apolipoprotein E, apolipoprotein A1 and prostaglandin-H2 D-isomerase by Western blot analyses and detect the downregulation of transthyretin, TGF-beta receptor type-1 and coiled-coil domain-containing protein 3 precursor.
CONCLUSIONS: These findings may help to elucidate the disease mechanisms and confirm the hypothesis of disturbed cholesterol and phospholipid metabolism in schizophrenia, and thus reveal the final role players. Moreover, a grouped protein expression analysis of apolipoprotein E, apolipoprotein A-I, and prostaglandin-H2 D-isomerase in cerebrospinal fluid from patients might be a potential diagnostic tool for schizophrenia.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20446881     DOI: 10.3109/15622971003758748

Source DB:  PubMed          Journal:  World J Biol Psychiatry        ISSN: 1562-2975            Impact factor:   4.132


  15 in total

Review 1.  Cerebrospinal fluid biomarker candidates of schizophrenia: where do we stand?

Authors:  Nenad Vasic; Bernhard J Connemann; Robert C Wolf; Hayrettin Tumani; Johannes Brettschneider
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2011-12-16       Impact factor: 5.270

2.  Cerebrospinal fluid diagnostics in first-episode schizophrenia.

Authors:  Laura Kranaster; Dagmar Koethe; Carolin Hoyer; Andreas Meyer-Lindenberg; F Markus Leweke
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2011-02-06       Impact factor: 5.270

Review 3.  Recent advances in quantitative neuroproteomics.

Authors:  George E Craft; Anshu Chen; Angus C Nairn
Journal:  Methods       Date:  2013-04-25       Impact factor: 3.608

4.  Multiplatform metabolome and proteome profiling identifies serum metabolite and protein signatures as prospective biomarkers for schizophrenia.

Authors:  Khaled Al Awam; Ida Sibylle Haußleiter; Ed Dudley; Rossen Donev; Martin Brüne; Georg Juckel; Johannes Thome
Journal:  J Neural Transm (Vienna)       Date:  2014-05-01       Impact factor: 3.575

Review 5.  Molecular substrates of schizophrenia: homeostatic signaling to connectivity.

Authors:  M A Landek-Salgado; T E Faust; A Sawa
Journal:  Mol Psychiatry       Date:  2015-09-22       Impact factor: 15.992

6.  APOA-I: a possible novel biomarker for metabolic side effects in first episode schizophrenia.

Authors:  Xueqin Song; Xue Li; Jinsong Gao; Jingping Zhao; Youhui Li; Xiaoduo Fan; Luxian Lv
Journal:  PLoS One       Date:  2014-04-07       Impact factor: 3.240

Review 7.  Potential biomarkers in psychiatry: focus on the cholesterol system.

Authors:  Alisa G Woods; Izabela Sokolowska; Regina Taurines; Manfred Gerlach; Edward Dudley; Johannes Thome; Costel C Darie
Journal:  J Cell Mol Med       Date:  2012-06       Impact factor: 5.310

8.  Altered apolipoprotein C expression in association with cognition impairments and hippocampus volume in schizophrenia and bipolar disorder.

Authors:  Christian Knöchel; Jonathan Kniep; Jason D Cooper; Michael Stäblein; Sofia Wenzler; Jan Sarlon; David Prvulovic; David E J Linden; Sabine Bahn; Pawel Stocki; Sureyya Ozcan; Gilberto Alves; Andre F Carvalho; Andreas Reif; Viola Oertel-Knöchel
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2016-08-22       Impact factor: 5.270

Review 9.  Proteomics, metabolomics, and protein interactomics in the characterization of the molecular features of major depressive disorder.

Authors:  Daniel Martins-de-Souza
Journal:  Dialogues Clin Neurosci       Date:  2014-03       Impact factor: 5.986

Review 10.  The proteome of schizophrenia.

Authors:  Juliana M Nascimento; Daniel Martins-de-Souza
Journal:  NPJ Schizophr       Date:  2015-03-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.